Please login to the form below

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

Opdivo improves survival in oesophageal cancer

BMS said that while Opdivo plus Yervoy hit its OS primary endpoint, it missed the PFS co-primary endpoint. ... The US Food and Drug Administration (FDA) accepted a priority review for BMS’ Opdivo plus chemotherapy combination in stomach cancer earlier

Latest news

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting. ... In patients with resection, the pCR rate increased further to 30.5% for those receiving the Opdivo/chemotherapy
Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

The first-line approval for Keytruda gives it an advantage over rival checkpoint inhibitor Opdivo (nivolumab) from Bristol Myers Squibb (BMS). ... BMS is also working towards gaining approval for Opdivo in the first-line setting, having revealed
FDA advisory committee to review oncology accelerated approvals

Similarly, BMS decided to withdraw the US indication for PD-1 inhibitor Opdivo (nivolumab) in SCLC which has progressed following prior therapies. ... As with Keytruda, Opdivo was granted an accelerated approval in this indication but subsequent
MSD withdraws Keytruda’s US indication for small cell lung cancer

Similarly, Bristol Myers Squibb decided to withdraw the US indication for PD-1 inhibitor Opdivo (nivolumab) in SCLC which has progressed following prior therapies. ... As with Keytruda, Opdivo was granted an accelerated approval in this indication but
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Bristol Myers Squibb (BMS) and Exelixis also recently revealed new analyses from a phase 3 study of their Opdivo (nivolumab) and Cabometyx (cabozantinib) combination in first-line, advanced RCC. ... Opdivo/Cabometyx was also associated with a disease

More from news
Approximately 155 fully matching, plus 230 partially matching documents found.

Latest Intelligence

Putting commercial intelligence at the heart of strategy

Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
20 for 2020 – Five pharma companies to watch

The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years ago, and 2020 is viewed ... Opdivo is being squeezed out of the market by Merck &Co/
Encouraging signs in biomarker R&D

In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.
2019: CRISPR and therapeutic gene editing comes of age

The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
Immuno-oncology in 2019: the rapid evolution continues

Opdivo will be just behind on around $6.8bn, with more rapid growth for both therapies expected this year. ... Opdivo is not a contender as a monotherapy or combination with chemo in front-line NSCLC, having failed key trials in the last few years.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

BMS appoints new commercial leader, Davies joins Eisai and more

The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda. ... BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains
BMS appoints oncology development head

On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Manufacturer. Indication. Notes. Nivolumab. Opdivo. Bristol-Myers Squibb. Front-line monotherapy in patients with unresectable and metastatic melanoma. ... Bristol-Myers Squibb’s Opdivo (nivolumab). Merck’s Keytruda (pembrolizumab). Genentech’s
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

Both nivolumab (Opdivo) and pembrolizumab received accelerated approval from the FDA for treating liver cancer, on the basis of efficacy and safety results from early phase trials that had overall response
A stumble, but not a fall – what’s next for Opdivo?

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results. ... Bristol-Myers Squibb's (BMS, $BMY) immunotherapy wonder drug Opdivo (nivolumab) was poised for lasting success.
Video: Immuno-oncology therapies

high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.
Video: Immuno-oncology therapies

However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...